{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:35:07Z","timestamp":1777880107647,"version":"3.51.4"},"reference-count":85,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW012487"],"award-info":[{"award-number":["D43TW012487"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) remains highly endemic in many low- and middle-income countries (LMICs), where challenges such as antiviral resistance and immune\/vaccine-escape mutations complicate disease management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This review synthesizes current data on HBV drug resistance, including the prevalence and distribution of resistance-associated mutations (RAMs), vaccine-escape mutations (VEMs), and immune-escape mutations (IEMs) in LMICs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>PubMed, Scopus, and Web of Science.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic search was conducted from 2014 to 2025 (last search date: August 04, 2025), and data were extracted from eligible studies. A random-effects meta-analysis was conducted to estimate pooled resistance rates and prevalences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 43,834 participants from 47 studies conducted in 28 LMICs were included. The overall antiviral resistance rate was 7.87% (95% CI (5.13\u201311.11)), with very high heterogeneity (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200999.7%). Lamivudine (3TC) and telbivudine (LdT) had the highest resistance rates. Asia consistently reported the greatest resistance, with rates of 32.45% for 3TC and 51.92% for LdT. In a subgroup analysis on economic regions, Lower-middle-income countries showed the highest pooled resistance rate at 10.61% (95% CI (5.21\u201317.51);\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200996.9%). The most frequently detected RAMs were rtM204V\/I, rtV173L, and rtL180M. The pooled prevalence of vaccine-escape mutations was 8.92% (95% CI (5.02\u201313.64);\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200978.4%). Immune-escape mutations were much more common, with a pooled prevalence of 55.66% (95% CI (28.10\u201381.53);\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200998.1%). The most prevalent mutations were sG145R\/A\/K, sQ129H\/R, sD144E\/A, sS143L\/T, and sP120S\/T. The pooled estimates in this study are reported and interpreted descriptively, given the substantial heterogeneity observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The remarkably high drug resistance rates and prevalence of immune and vaccine-escape mutations suggest notable burdens of resistance, especially for drugs with low genetic barriers such as lamivudine and telbivudine, underscoring the growing challenges in achieving the WHO 2030 reduction goals, and highlighting the need for enhanced surveillance, adoption of potent antiviral regimens such as tenofovir disoproxil fumarate, and continuous vaccine efficacy monitoring. However, the results should be interpreted with caution due to the very high heterogeneity observed in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>International prospective register of systematic reviews (PROSPERO) under the ID: CRD420251030302.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361261431606","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:51:58Z","timestamp":1774605118000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review and meta-analysis of hepatitis B virus drug resistance and escape mutations in low- and middle-income countries"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9936-6802","authenticated-orcid":false,"given":"Esther M. E.","family":"Asamoah","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia A.","family":"Asantewaa","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3880-2035","authenticated-orcid":false,"given":"Samuel N.-A.","family":"Yartey","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-9564","authenticated-orcid":false,"given":"Nicholas I.","family":"Nii-Trebi","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, University of Ghana School of Biomedical and Allied Health Sciences, Korle-Bu, Accra, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Donkor","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Ghana Medical School, P. O. Box KB 4236, Korle Bu, Accra, KB 4236, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Hepatitis B https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b (2025 accessed 24 June 2025)."},{"key":"e_1_3_4_3_2","unstructured":"Tripathi N Mousa OY. Hepatitis B. In: Stat Pearls. Treasure Island (FL): Stat Pearls Publishing http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555945\/ (2025 accessed 24 June 2025)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.33073\/pjm-2020-044"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14050986"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2024.05.004"},{"key":"e_1_3_4_7_2","unstructured":"Global Health Sector Strategies https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/strategies\/global-health-sector-strategies (2022 accessed 23 June 2025)."},{"key":"e_1_3_4_8_2","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries https:\/\/www.who.int\/publications\/i\/item\/9789240091672 (2024 accessed 23 June 2025)."},{"key":"e_1_3_4_9_2","unstructured":"Global progress report on HIV viral hepatitis and sexually transmitted infections 2021 https:\/\/www.who.int\/publications\/i\/item\/9789240027077 (2021 accessed 23 June 2025)."},{"key":"e_1_3_4_10_2","unstructured":"Hepatitis https:\/\/www.who.int\/multi-media\/details\/elimination-of-hepatitis-by-2030 (2020 accessed 24 July 2025)."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i19.5708"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw049"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000619"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13525"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_3_4_16_2","unstructured":"World Bank country classifications by income level for 2024-2025. World Bank Blogs https:\/\/blogs.worldbank.org\/en\/opendata\/world-bank-country-classifications-by-income-level-for-2024-2025 (2024 accessed 9 April 2025)."},{"key":"e_1_3_4_17_2","unstructured":"Rayyan \u2013 Intelligent Systematic Review - Rayyan https:\/\/www.rayyan.ai\/ (2021 accessed 19 November 2024)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.32383\/appdr\/84804"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.6583"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13071273"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3333"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12223-018-0650-z"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.4102\/ajlm.v11i1.1677"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu630"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3055"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.36233\/0507-4088-175"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1202342"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191970"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3060"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143869"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trv077"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00936-21"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276687"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190149"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13052"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24853"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S315299"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.08.008"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2022.105371"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-017-0136-0"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11112622"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.04.002"},{"key":"e_1_3_4_43_2","article-title":"Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment- na\u00efve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study","volume":"12","author":"Hoang M-C","year":"2025","unstructured":"Hoang M-C, Duong H-Q, Le V-D, et al. Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment- na\u00efve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study. Ther Adv Infect Dis 2025; 12: 20499361251344784.","journal-title":"Ther Adv Infect Dis"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i35.5314"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-013-0054-3"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2020.10.012"},{"key":"e_1_3_4_47_2","first-page":"20","article-title":"Hepatitis B virus genetic heterogeneity and drug resistance among jaundiced patients at Coast General Teaching and Referral Hospital, Mombasa County, Kenya","volume":"15","author":"Kasera GO","year":"2021","unstructured":"Kasera GO, Nyamache AK, Onyango OK, et al. Hepatitis B virus genetic heterogeneity and drug resistance among jaundiced patients at Coast General Teaching and Referral Hospital, Mombasa County, Kenya. Int J Health Sci 2021; 15: 20\u201325.","journal-title":"Int J Health Sci"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.10.039"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-016-0636-x"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2222-1808(16)61079-4"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2023.02.013"},{"key":"e_1_3_4_52_2","first-page":"23","article-title":"Resistance of HBV to nucleoside reverse transcriptase inhibitors and its impact on surface antigen in HBV-HIV co-infected patients in Abidjan","volume":"5","author":"Olivier GL","year":"2022","unstructured":"Olivier GL, Philippe NJ-L, Emmanuel B, et al. Resistance of HBV to nucleoside reverse transcriptase inhibitors and its impact on surface antigen in HBV-HIV co-infected patients in Abidjan. Int J Biochem 2022; 5: 23\u201340.","journal-title":"Int J Biochem"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-021-01493-4"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2218076"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2942"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242577"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16040592"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10070491"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0121"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S135420"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2024.105733"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15112188"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.13173"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238839"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2018.05.007"},{"key":"e_1_3_4_66_2","unstructured":"World Map - Simple | Create a custom map. MapChart https:\/\/mapchart.net\/world.html (accessed 30 October 2025)."},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25730"},{"key":"e_1_3_4_68_2","article-title":"An oxford nanopore technology-based hepatitis B virus sequencing protocol suitable for genomic surveillance within clinical diagnostic settings","author":"Tshiabuila D","year":"2024","unstructured":"Tshiabuila D, Choga W, James SE, et al. An oxford nanopore technology-based hepatitis B virus sequencing protocol suitable for genomic surveillance within clinical diagnostic settings. medRxiv 2024.","journal-title":"medRxiv"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11071011"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02399.x"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"e_1_3_4_72_2","unstructured":"DHANJAL A. Tenofovir resistance in patients with HBV. EASL-The home of hepatology https:\/\/easl.eu\/news\/tenofovir-resistance-in-patients-with-hbv\/ (2019 accessed 31 August 2025)."},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i17.1919"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104548"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27563"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01064-18"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00836-20"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13753"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S389853"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.036"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32865-1"},{"key":"e_1_3_4_83_2","first-page":"153","article-title":"Molecular analysis of hepatitis B virus reverse transcriptase domain for mutations associated with viral resistance in Pakistani patients","volume":"27","author":"Mahmood M","year":"2021","unstructured":"Mahmood M, Jameel S, Rahman ZU, et al. Molecular analysis of hepatitis B virus reverse transcriptase domain for mutations associated with viral resistance in Pakistani patients. Viral Hepatit Dergisi-Viral Hepatitis J 2021; 27: 153\u2013158.","journal-title":"Viral Hepatit Dergisi-Viral Hepatitis J"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i1.145"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006629"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2473222"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361261431606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361261431606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361261431606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:02:05Z","timestamp":1777593725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361261431606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":85,"alternative-id":["10.1177\/20499361261431606"],"URL":"https:\/\/doi.org\/10.1177\/20499361261431606","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"20499361261431606"}}